Drug Profile

Ceralasertib - AstraZeneca/University of Pennsylvania

Alternative Names: AZD 6738

Latest Information Update: 17 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca; University of Pennsylvania
Developer Acerta Pharma; AstraZeneca; Dana-Farber Cancer Institute; Gustave Roussy; National Cancer Institute (France); Samsung Medical Center; University of California at San Francisco; University of Pennsylvania
Class Antineoplastics; Cyclopropanes; Imines; Ketones; Morpholines; Organic sulfur compounds; Pyridines; Pyrimidines; Pyrroles; Small molecules
Mechanism of Action ATR protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Discontinued Cholangiocarcinoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Diffuse large B cell lymphoma; Gynaecological cancer; Haematological malignancies; Malignant melanoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Type 1 diabetes mellitus

17 Sep 2026 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in United Kingdom (IV)
02 Jun 2026 Efficacy, pharmacodynamics and adverse events data from a phase II trial in Malignant melanoma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
05 Feb 2026 Discontinued - Phase-I for Chronic myelomonocytic leukaemia (Recurrent, Metastatic disease, Second-line therapy or greater) in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com